학술논문
A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemictabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma.
Document Type
Journal
Author
Source
Subject
Language
English
ISSN
15277755